ISPOR’s 1st PLENARY OF 18th ANNUAL EUROPEAN CONGRESS FOCUSES ON LIFECYCLE APPROACH TO DECISION MAKING ON HEALTH TECHNOLOGIES

Published Nov 9, 2015
Milan, Italy—November 9, 2015—The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 18th Annual European Congress first plenary session — Strategy in Motion: The Current and Future Lifecycle Approach to Decision Making on Health Technologies — was held this morning at the MiCo – Milano Congressi in Milan, Italy. The plenary was moderated by François Meyer, MD, Advisor to the President, International Affairs, French National Authority for Health (HAS), Saint-Denis La Plaine, France and featured speakers:

- Hans-Georg Eichler, MD, MSc, Senior Medical Officer, European Medicines Agency (EMA), London, UK

- Jerome Boehm, Team Leader, Health Technology Assessment, Directorate-General for Health and Food Safety, European Commission, Brussels, Belgium - Finn Børlum Kristensen, MD, PhD, Professor, Health Services Research & Health Technology Assessment, University of Southern Denmark and Director, EUnetHTA Secretariat, Danish Health and Medicines Authority, Copenhagen, Denmark - Mirella Marlow, MA, MBA, Programme Director, Devices and Diagnostics Systems, Centre for Health Technology Evaluation, National Institute for Health and Care Excellence (NICE), London, UK The Strategy in Motion plenary focused on the work underway within the Adaptive Pathways to Patients initiative for drugs. The panel presented their views on adaptive pathways as the preferred approach to developing, licensing, assessing, appraising, and paying for new medicines and treatments. The panel also examined the European Commission's health technology assessment (HTA) network plans following the transition of the successful EUnetHTA program, which built strength and dialogue both across Europe and globally. Released presentations from the ISPOR 18th Annual European Congress are available at http://www.ispor.org/Event/ReleasedPresentations/2015Milan. ISPOR’s 18th Annual European Congress may be followed on social media using the hashtag #ISPORMilan.

###

Related Stories

ISPOR Task Force Addresses Critical Gap in Surrogate Endpoint Guidance

May 28, 2026

Value in Health, announced the publication of an ISPOR Good Practices Report providing guidance on the use of surrogate endpoint evaluation methods in health technology assessment (HTA) decision making. The report, “Methods for Evaluation of Surrogate Endpoints for HTA Decision Making: A Good Practices Report of an ISPOR Task Force,” was published in the May 2026 issue of Value in Health.

How Is Health Valued in the United Kingdom? We Finally Have a Better Answer

May 27, 2026

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced today the publication of a pair of companion articles that together establish both the methodological foundation of the first definitive UK value set for the EQ-5D-5L and the practical implications of adopting it—thus equipping health technology assessment decision makers with a UK value set suitable for informing policy. The articles were featured in the May 2026 issue of Value in Health.

ISPOR Announces 2026-2027 Board of Directors

May 26, 2026

ISPOR—The Professional Society for Health Economics and Outcomes Research announced its 2026-2027 board of directors who will assume office on July 1, 2026.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×